XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference

    NEW YORK, October 29 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals
 Ltd. (NASDAQ:   XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur,
 the Company's Chief Executive Officer, is scheduled to present at the
 Acumen BioFin Rodman & Renshaw 9th Annual Health Care Conference. Mr.
 Bentsur will present an overview of the Company including a discussion of
 Bicifadine, the Company's late-stage clinical compound for the treatment of
 neuropathic pain. Mr. Bentsur's presentation will take place on Monday,
 November 5, 2007 at 8:50 am EST at the New York Palace Hotel in New York
 City.
     A live webcast of the presentation will be available at:
 http://www.wsw.com/webcast/rrshq12/xtlb. An archived version of the webcast
 will be available following the conclusion of the live presentation.
     About XTL Biopharmaceuticals Ltd.
     XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
 therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
 developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor,
 for the treatment of diabetic neuropathic pain. XTL is also developing
 several novel pre-clinical hepatitis C small molecule inhibitors. XTL also
 has an active in-licensing and acquisition program designed to identify and
 acquire additional drug candidates. XTL is publicly traded on the NASDAQ,
 London, and Tel-Aviv Stock Exchanges (NASDAQ:   XTLB; LSE: XTL; TASE: XTL).
     Contact
 
     Ron Bentsur, Chief Executive Officer
     Tel: +1-845-267-0707 ext. 225
 
 

SOURCE XTL Biopharmaceuticals Ltd